Loading
A phase 2 trial of Bevacizumab, Atezolizumab, Durvalumab in hepatocellular carcinoma, run by Replimune, Inc., now recruiting.
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC is a phase 2 interventional study registered as NCT05733598 by Replimune, Inc., with 60 participants planned, started 2024-08-01 and due to reach its primary completion in 2027-12-01. Interventions recorded: RP2, Bevacizumab, Atezolizumab, Durvalumab, RP2 Monotherapy. Conditions listed: Hepatocellular Carcinoma, Biliary Tract Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Durvalumab, Bevacizumab, Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Durvalumab, Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Durvalumab, Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/